KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) FCF Margin (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed FCF Margin for 18 consecutive years, with 23.53% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin fell 341.0% year-over-year to 23.53%; the TTM value through Mar 2026 reached 27.57%, up 555.0%, while the annual FY2025 figure was 28.45%, 265.0% up from the prior year.
  • FCF Margin hit 23.53% in Q1 2026 for Regeneron Pharmaceuticals, down from 23.74% in the prior quarter.
  • Across five years, FCF Margin topped out at 3919.8% in Q1 2022 and bottomed at 9.48% in Q2 2024.
  • Average FCF Margin over 5 years is 345.89%, with a median of 26.94% recorded in 2025.
  • Year-over-year, FCF Margin soared 389632bps in 2022 and then plummeted -388219bps in 2023.
  • Regeneron Pharmaceuticals' FCF Margin stood at 1567.7% in 2022, then plummeted by -98bps to 24.41% in 2023, then grew by 15bps to 28.06% in 2024, then dropped by -15bps to 23.74% in 2025, then decreased by -1bps to 23.53% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 23.53%, 23.74%, and 30.57% for Q1 2026, Q4 2025, and Q3 2025 respectively.